

# GENERALIZED MYASTHENIA GRAVIS (gMG)

## OVERVIEW

Myasthenia gravis (MG) is a debilitating, chronic and progressive autoimmune neuromuscular disease that can occur at any age, but most commonly begins for women before the age of 40 and men after the age of 60.<sup>1-4</sup> It typically begins with weakness in the muscles that control the movements of the eyes and eyelids, and often progresses to the more severe and generalized form, known as generalized myasthenia gravis (gMG), with weakness of the head, neck, trunk, limb and respiratory muscles.<sup>4</sup>

While most patients with gMG can be managed with therapies for MG, 10-15% of patients fail to respond adequately to or cannot tolerate multiple therapies for MG and continue to suffer profound muscle weakness and severe disease symptoms that limit function.<sup>5-7</sup> Between 53 and 75% of these patients also have auto-antibodies against the acetylcholine receptor (AChR) that plays an important role in the communication between nerves and muscles.<sup>6,8-10</sup>

Patients with gMG who fail to respond adequately to or cannot tolerate multiple therapies for MG and who are anti-AChR antibody-positive represent an estimated 5-10% of patients with MG.<sup>5,9,11,12</sup>

## SYMPTOMS AND COMPLICATIONS

Patients with gMG can suffer from slurred speech, choking, impaired swallowing, double or blurred vision, disabling fatigue, immobility requiring assistance, shortness of breath and episodes of respiratory failure. Complications, exacerbations and myasthenic crises can require hospital and intensive care unit admissions with prolonged stays, and can be life-threatening.<sup>2,3,13</sup>

## CAUSES

In MG, an autoimmune response leads to progressive inflammation and damage at the neuromuscular junction (NMJ), the area where nerve cells reach the muscles they control. This damage impairs the communication between nerve and muscle, which in turn leads to a loss of normal muscle function.<sup>2,3</sup>

In patients with MG who are anti-AChR antibody-positive, these auto-antibodies bind to the AChR, a receptor located on muscle cells in the NMJ and used by nerve cells to communicate with the muscle. The binding of these auto-antibodies to the AChR activates the complement cascade, which is another component of the immune system. The chronic complement activation by anti-AChR antibodies results in the localized inflammation and destruction of the muscle membrane at the NMJ.<sup>10,14,15</sup>

10-15% of patients with gMG fail to respond adequately to or cannot tolerate multiple therapies for MG.<sup>5,6</sup>

Patients continue to suffer profound muscle weakness and severe disease symptoms that impact function.<sup>5-7</sup>



Unresolved  
gMG symptoms  
despite existing  
therapy

These patients are at risk of disease exacerbations and crises, which can be life-threatening and require hospital and intensive care unit admissions with prolonged stays.<sup>17,18</sup>

In 5-10% of patients with MG who fail to respond adequately to or cannot tolerate multiple therapies for MG, chronic complement activation by anti-AChR antibodies is an important underlying cause of the disease.<sup>5,9,11,12</sup>


## DIAGNOSIS AND MANAGEMENT

MG is typically diagnosed with a physical examination to evaluate distinct symptoms of muscle weakness such as impaired eye movement, droopy eyelids, inability to hold the head straight, speech disturbances and limb weakness. Blood tests for anti-AChR or other antibodies are also used, as well as nerve and muscle stimulation and chest computed tomography or magnetic resonance imaging.<sup>3,16</sup>

Prior to the availability of complement inhibition, therapies for gMG included acetylcholinesterase inhibitors, corticosteroids and other immunosuppressive therapies.<sup>3,6</sup> Plasma exchange and intravenous administration of immunoglobulin to remove or neutralize abnormal antibodies from the blood, and the infusion of antibodies from donated blood, may be used as "rescue therapy" for severe disease exacerbations.<sup>6</sup> The surgical removal of the thymus gland, which is often abnormal in patients with MG, is recommended for patients who develop tumors of the thymus gland (thymoma) and some patients without thymoma.<sup>3</sup>

**For more information on MG, visit the Myasthenia Gravis Foundation of America website at [myasthenia.org](http://myasthenia.org).**

## ANTI-ACHR ANTIBODY-POSITIVE MG <sup>4,8,10,19</sup>



ACh released by nerve cells binds to AChR on muscle cells, resulting in muscle activation.

Anti-AChR antibodies bind to AChRs, which can directly interfere with signaling and triggers the activation of the complement cascade (C1 complex). The complement cascade produces the MAC that damages the muscle cell membrane, resulting in loss of AChRs.

The localized destruction of the NMJ impairs the communication between nerve and muscle, which in turn leads to a loss of normal muscle function.

Acetylcholine (ACh), Neuromuscular Junction (NMJ), Acetylcholine Receptor (AChR), Membrane Attack Complex (MAC)

### References

- Huda R, Tüzün E, Christadoss P. Targeting complement system to treat myasthenia gravis. *Rev. Neurosci.* 2014; 25(4): 575–583.
- Howard JF, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. *Muscle Nerve.* 2013;48(1):76–84.
- National Institute of Neurological Disorders and Stroke. Myasthenia Gravis Fact Sheet. Publication date May 2017. [http://www.ninds.nih.gov/disorders/myasthenia\\_gravis/detail\\_myasthenia\\_gravis.htm](http://www.ninds.nih.gov/disorders/myasthenia_gravis/detail_myasthenia_gravis.htm). Accessed October 12, 2017.
- Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. *Lancet Neurol.* 2009–8(5): 475–490.
- Silvestri N, Wolfe G. Treatment-refractory myasthenia gravis. *J. Clin Neuromuscul Dis.* 2014;15(4):167–178.
- Howard J. Targeting the Complement System in Refractory Myasthenia Gravis. *Supplement to Neurology Reviews.* February 2016.
- Sanders DB, Wolfe, GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology.* 2016;87(4):419–25.
- Buzzard K.A., Meyer N. J., Hardy T. A., Riminton D. S. and Reddel S. W. Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. *Muscle Nerve.* 2015;52(2):204–210.
- Suh J., Goldstein JM, Nowak RJ. Clinical Characteristics of Refractory Myasthenia Gravis Patients. *Yale J Biol Med.* 2013;86(2):255–260.
- Conti-Fine, et al. Myasthenia gravis: past, present, and future. *J Clin Invest.* 2006;116:2843–2354.
- Howard J. Myasthenia Gravis – A summary. Myasthenia Gravis Foundation of America. <http://www.myasthenia.org/HealthProfessionals/ClinicalOverviewofMG.aspx>. Accessed October 12, 2017.
- Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. *Muscle Nerve.* 2008;37(2):141–9.
- Sathasivam S. Diagnosis and management of myasthenia gravis. *Progress in Neurology and Psychiatry.* January/February 2014.
- Tüzün E, Huda R, Christadoss P. Complement and cytokine based therapeutic strategies in myasthenia gravis. *J Autoimmun.* 2011;37(2):136–143.
- Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? *Expert Rev. Clin. Immunol.* 2012;8(5):427–428.
- Li Y, Arora Y, Levin K. Myasthenia gravis: Newer therapies offer sustained improvement. *Cleve Clin J Med.* 2013;80(11):711–721.
- Souayah N, Nasar A, Suri MF, et al. *Int J Biomed Sci.* 2009;5(3):209–214.
- Engel-Nitz N, et al. Poster 146; ICNMD 2016.
- Kusner LL, Kaminski HJ. *Ann NY Acad Sci.* 2012;1274(1):127–132.

US/UNB-gMG/17/0024